| |
Digital transformation, AI, big data, and regulatory action—these four trends are shaping the healthcare industry. From new technologies to billion-dollar research funding, there are plenty of lucrative investment opportunities to be had. Learn more.
|
|
Today’s Big NewsAug 21, 2023 |
|
October 16-17 | Boston, MA
Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book your seat today and save $200!
|
|
| By Angus Liu The FDA will hold an advisory committee meeting to discuss confirmatory trial data for Amgen's Lumakras in KRAS-mutated lung cancer. This comes after a bumpy stretch for the medicine since its debut in 2021. |
|
|
|
By Annalee Armstrong Exactly a month after Gilead revealed it had shelved a myelodysplastic syndromes program for magrolimab, the molecule has been placed under a partial clinical hold by the FDA for its phase 3 acute myeloid leukemia studies. |
By Conor Hale First spun out of Stanford University in late 2019, the company's deep learning platform helps design small-molecule drug compounds and predicts how they interact with the body. |
By Gabrielle Masson Layoffs in the biotech industry for 2023 have matched the total number of companies that cut staff in all of 2022, with 119 biopharmas reporting workforce reductions so far this year, according to an analysis of Fierce Biotech data. |
By Kevin Dunleavy Merck cancer superstar Keytruda is projected to be the world’s top selling drug by a huge margin in 2028, according to a report by Evaluate. On its list of top 10 drugs by sales in 2028, Keytruda is expected to top the $30 billion mark, with no other therapy predicted to reach $20 billion in sales. |
By Conor Hale PhenomeX was formed earlier this year after Berkeley Lights bought up IsoPlexis, a former Fierce Medtech Fierce 15 winner. |
By James Waldron What could be hotter than Moderna getting in the Claudin18.2 race? How about pairing up this mRNA therapeutic cancer vaccine with a solid tumor-targeting CAR-T? |
By Andrea Park ICU Medical plans to lay off several dozen workers in the process of permanently shutting down a manufacturing facility in Minnesota. |
By Kevin Dunleavy With the FDA signing off on Regeneron and Bayer’s high-dose Eylea, the companies are set to take on Roche’s Vabysmo in a high-stakes battle for the massive eye disease market. |
By Andrea Park Satio is building rapid, patch-based devices to collect both dried blood spots and whole blood samples, which are now set to be combined with an Ebola diagnostic from Senegal’s Institut Pasteur de Dakar to create an all-in-one blood collecting and testing platform for the virus. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
